Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals plc enters the 21 June 2026 daily file with a stronger evidence rail than a plain ticker scan would suggest. The latest supplied financial filing is the 10-Q for the period ending 31 March 2026, which records $1.07B of revenue from contracts with customers, $336.6M of operating income, $293.1M of net income attributable to parent and diluted earnings per share of $4.43. That is the anchor: a named pharmaceutical issuer with current SEC-filed revenue, profit, cash and share-count data, not a loose market rumour.

The company describes itself on its official website as focused on improving patients' lives by identifying, developing and commercialising products that address unmet medical needs. The product rail supplied for this report names Xywav, with late-breaking SLEEP 2026 data across narcolepsy and idiopathic hypersomnia, and Zepzelca, with an update on the Phase 3 LAGOON trial in second-line small cell lung cancer. Those source facts matter because they connect the equity to the operating business underneath it: medicines, patient groups, clinical evidence and commercial execution.

The balance sheet and cash figures are equally central. The 10-Q for the period ending 31 March 2026 lists assets of $11.86B, stockholders' equity attributable to parent of $4.53B, cash and cash equivalents of $1.84B, net cash provided by operating activities of $408.2M, payments to acquire property, plant and equipment of $19.7M, inventory net of $437.5M and an increase in inventories of $77.8M. The same filing gives diluted weighted average shares outstanding of 66.1M. The filing evidence also says royalties and contract revenues decreased versus the same period in 2025, primarily because of lower Hikma royalty revenue after a reduced applicable royalty rate on net sales of Hikma's high sodium oxybate authorised generic, while cost of product sales increased because of higher royalty expenses, increased inventory provisions and a $7.6M higher fair value step-up expense.

No TradingView or chart route was supplied in this evidence pack, so this daily layer does not invent candle levels, support zones, moving averages or price action. The market mechanism that can be described from the supplied rail is instead a filing mechanism: a profitable pharmaceutical company with fresh quarterly numbers, named product evidence, SEC insider and resale filing trail in June, and official issuer updates around sleep medicine and oncology. The share story here is therefore driven by what the public documents prove, not by an imagined line on a chart.

The named recent developments are clustered on the SEC rail. The source list includes Form 144 filings dated 10 June 2026 and 15 June 2026, Form 4 filings dated 12 June 2026 and 17 June 2026, an annual report to shareholders dated 8 June 2026 and a DEFA14A additional proxy filing dated 8 June 2026. It also includes an 8-K dated 5 May 2026 for the company's first-quarter results announcement and an 8-K dated 29 May 2026 as an official SEC source page. The filings prove public disclosure activity; they do not, by themselves, prove a new clinical result, a price move or a change in guidance unless that fact is supplied in the rail.

The thin part of the file is also important. The evidence does not provide current share price, valuation multiples, guidance, dividend policy, buyback activity, complete product-level sales, management commentary beyond the supplied filing excerpts, or detailed trial outcomes for Xywav and Zepzelca. That limit keeps the story honest: the proven case today is a profitable, cash-generative pharmaceutical issuer with named product and filing activity, while the deeper market argument would require fuller earnings commentary, product sales detail, trial data and a verified chart source.